Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495672 | 0.90 | CASR (0.76) | CASR | |
| SCHEMBL2496687 | 0.88 | CASR (0.79) | CASR | |
| SCHEMBL2500089 | 0.88 | CASR (0.72) | CASR | |
| SCHEMBL2502803 | 0.87 | CASR (0.75) | CASR | |
| SCHEMBL2498050 | 0.86 | CASR (0.71) | CASR | |
| SCHEMBL2493626 | 0.85 | CASR (0.75) | CASR | |
| SCHEMBL2498259 | 0.85 | CASR (0.81) | CASR | |
| SCHEMBL2496420 | 0.84 | CASR (1.00) | CASR | |
| SCHEMBL2495648 | 0.84 | CASR (0.84) | CASR | |
| SCHEMBL2980689 | 0.84 | CASR (1.00) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709006-A1 | BENZIMIDAZOLE DERIVATIVES | Novartis AG (CH) | 2006-10-11 | — | — | EP | claimed |
| WO-2005068433-A9 | BENZIMIDAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2005-09-15 | — | — | WO | claimed |
| WO-2005068433-A1 | BENZIMIDAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | claimed |
| US-8030497-B2 | Benzimidazole derivatives | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| US-8030497-B2 | Benzimidazole derivatives | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| US-8030497-B2 | Benzimidazole derivatives | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| EP-2124893-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CALCILYTIC AGENT | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-20090170921-A1 | Benzimidazole derivatives | NOVARTIS AG (CH) | 2009-07-02 | — | — | US | disclosed |
| US-20090170921-A1 | Benzimidazole derivatives | NOVARTIS AG (CH) | 2009-07-02 | — | — | US | disclosed |
| US-20090170921-A1 | Benzimidazole derivatives | NOVARTIS AG (CH) | 2009-07-02 | — | — | US | disclosed |
| WO-2008107390-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CALCILYTIC AGENT | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| EP-1709006-A1 | BENZIMIDAZOLE DERIVATIVES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005068433-A9 | BENZIMIDAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005068433-A1 | BENZIMIDAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170921-A1 | Benzimidazole derivatives | CYP3A7, UGT2B7, CYP2B6 | CASR 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.